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ABSTRACT
Retroviral insertional mutagenesis has been instru-
mental for the identification of genes important in
cancer development. The molecular mechanisms
involved in retroviral-mediated activation of proto-
oncogenes influence the distribution of insertions
within specific regions during tumorigenesis and
hence may point to novel gene structures. From a
retroviral tagging screen on tumors of 1767 SL3-3
MLV-infected BALB/c mice, intron 2 of the AP-1
repressor Jdp2 locus was found frequently targeted
by proviruses resulting in upregulation of non-
canonical RNA subspecies. We identified several
promoter regions within 1000bp upstream of exon
3 that allowed for the production of Jdp2 protein
isoforms lacking the histone acetylase inhibitory
domain INHAT present in canonical Jdp2. The
novel Jdp2 isoforms localized to the nucleus and
over-expression in murine fibroblast cells induced
cell death similar to canonic Jdp2. When expressed
in the context of oncogenic NRAS both full length
Jdp2 and the shorter isoforms increased ancho-
rage-independent growth. Our results demonstrate
a biological function of Jdp2 lacking the INHAT
domain and suggest a post-genomic application
for the use of retroviral tagging data in identifying
new gene products with a potential role in
tumorigenesis.
INTRODUCTION
The cJun dimerization protein 2 (Jdp2) gene encodes a
163-amino-acid protein, Jdp2, initially discovered as an
inhibitor of AP-1/TRE (TPA response element)- and
AP-1/CRE (cyclic AMP response element)-mediated
transcription through heterodimerization with Jun and
ATF2, respectively (1,2). Additionally, Jdp2 may form
homodimers and heterodimerize with JunD, JunB, the
CCAAT/enhancer-binding protein C/EBPg and C/EBP
homologous protein (CHOP) (1,3–5). Jdp2 has been
shown to inhibit p300/ATF2-mediated transactivation of
cJunuponretinoic-acid-induced commitmentofmurine F9
cells by recruiting histone deacetylase 3 (HDAC3) to the
promoter of cJun (6), and to inhibit the histone acetyltrans-
ferase activity (7). This inhibition of histone acetyltransfer-
ase (INHAT) activity is associated with the N-terminal
domain encoded by exon 2. In addition to acting as
a transcriptional repressor, Jdp2 also directly associates
with the progesterone receptor (PR) and potentiates
ligand-dependent PR-mediated transactivation (8).
Furthermore, Jdp2 in a complex with CHOP10 was
recently shown to strongly enhance TRE but not CRE-
dependent transcription (5).
Jdp2 is involved in diverse processes. Over-expression
in vitro leads to diﬀerentiation of osteoclast (9) and myo-
blast (10) cell lines, and recent information from knock-
out mice has shown that Jdp2 works as a repressor of
adipocyte diﬀerentiation (11). The underlying mechanism
was shown to involve the inhibition of histone H3 acetyla-
tion of the promoter of the adipogenesis-related gene
C/EBPd (11). In other settings, Jdp2 appears to be
involved in the inhibition of apoptosis (12,13), as well as
in p16
Ink4a-mediated induction of replicative senescence
(14). Finally, general inhibition of the AP-1 complex by
expression of Jdp2 speciﬁcally in the heart correlates with
the induction of atrial dilatation (15).
Depending on the context, Jdp2 displays both onco-
genic (16–20) and tumor-suppressive (10,21) properties.
The regulation of Jdp2 is poorly understood. At the
RNA level, a ubiquitous expression pattern involving sev-
eral mRNA species is observed (2,18). Furthermore, upon
exogenic insults the C-terminus of the Jdp2 protein is
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The murine leukemia virus (MLV) is a non-oncogene
bearing retrovirus, which induces lymphomas in suscepti-
ble mice by insertional mutagenesis of host genes.
Assuming random integration, superimposing retroviral
insertion sites from a cohort of infected mice reveals
common integration sites (CIS), loci deﬁned as having
signiﬁcantly more insertions than would be expected by
chance (24). CISs point to potential cancer-associated
genes that have been deregulated by the integrated retro-
virus. Various modes of activation have been proposed
according to the position and transcriptional orientation
of the virus relative to the activated gene. Two commonly
observed activation mechanisms are enhancer and pro-
moter activation (25). In the latter case, transcription initi-
ates from the provirus promoter resulting in a virus-host
fusion mRNA. Enhancer activation refers to positive
inﬂuence from cis-elements in the proviral enhancer on
the promoter of the host gene. Enhancer activation may
occur over large distances, and for unknown reasons there
appears to be a selection for the opposite (integration
upstream of the host gene) or the same (integration
downstream of host gene) transcriptional orientation of
provirus as compared to host gene.
We here describe the usage of integration distribution
patterns in Jdp2 to identify novel transcriptional struc-
tures in the second intron of the Jdp2 gene resulting
in the activation of Jdp2 protein isoforms. Using assays
for cell survival and colony formation, we demonstrate
a functional activity of these novel isoforms that lack
the N-terminal INHAT domain. Our results suggest a gen-
eral approach of using retroviral tagging data to identify
transcriptional structures and possible protein isoforms
of genes involved in cancer development.
MATERIALS AND METHODS
Identification of integration sites
Newborn BALB/c mice were infected with SL3-3 MLV
and treated as described previously (26). On sickness or
observation of tumors, mice were sacriﬁced, and splenic
and thymic tumors removed and stored at  808C.
Genomic DNA from tumors was isolated using DNeasy
Tissue Kit (Qiagen) and provirus integration sites were
identiﬁed using the Splinkerette-based PCR method as
described (26).
PCR screening of the 30 end of Jdp2 intron 2 for inte-
grations was done on 0.05–0.5mg genomic tumor DNA
using recombinant Taq DNA polymerase (Invitrogen) fol-
lowing the manufacturer’s recommendations, and using
virus LTR-speciﬁc primers (either LTR-2620, 50-gaattcga
tatcgatccccggtcatctggg-30 or LTR-440, 50-ttcataaggcttagcc
agctaactgcagt-30) together with a reverse exon 3-speciﬁc
primer Exon3-52, 50-ttcttcttgttccggcatct-30.
RT-PCR and quantitative real-time PCR
Total RNA was extracted from tumor samples using
TRIZOL (Invitrogen) and stored immediately at  808C
until use. The integrity of the isolated RNA was assessed
by visual inspection of the intensity of the 28S and 18S
ribosomal bands on a non-denaturating ethidium-
bromide-stained agarose gel. RNA quantity was deter-
mined spectrophotometrically. Two mg total RNA was
reverse transcribed using the First Strand cDNA
Synthesis Kit (Fermentas) following the manufacturer’s
recommendation with the provided poly(dT) oligo. To
look for alternative splicing between published exons 1a
through 1d, PCR reactions were done with forward pri-
mers Exon1a-154 (50-tgggcaccgcgcctgcagcag-30), Exon1b-
148 (50-ggaggagcgcgagcat-30), Exon1c-70 (50-gctctggctgggt
taggagggaac-30) or Exon1d-150 (50-cagctgcctctctccatctt-30)
and reverse primer Intron2-87 (50-tccttcgctcttcttcctcgtctag
ctt-30) using 1/500 of the cDNA (corresponding to 4ng
of total RNA) per PCR reaction (Taq polymerase,
Invitrogen). Each PCR reaction consisted of an initial
melting step at 958C for 5min followed by 35 cycles of
ampliﬁcation, each consisting of a 30s melting step at
958C, annealing at 55–608C for 30s and elongation at
728C for 45s. A ﬁnal elongation step at 728C was done
for 10min. Quantitative real-time PCR (QRT-PCR) was
done using Platinum SYBR Green QRT-PCR SuperMix
UDG (Invitrogen) following the manufacturer’s recom-
mendations. Reactions in Figures 5 and 6 were run in
triplicates at least two times on a Mx3005 apparatus
(Stratagene) with cDNA corresponding to 10ng of total
RNA, whereas the initial screen in Figure 2 was done
two times in duplicate. Relative quantiﬁcation was done
with the Window-of-Linearity-based method applying
LinReqPCR software (version 11) using an averaged
ampliﬁcation eﬃciency per amplicon per run (27). We
estimated an approximate copy number (absolute quanti-
ﬁcation) by relating threshold cycles of unknown samples
to a standard curve made from amplicon-containing plas-
mid dilutions. The signal was normalized to the expression
level of the TATA box binding protein (Tbp) or the
geometric mean of Tbp and Actb ( -Actin) (28). Primers
in Jdp2 were: Exon2-51, 50-gaggtgaaactgggcaagag-30;
Exon3-52, 50-ttcttcttgttccggcatct-30; Intron2-55, 50-tttgctg
agatgtgggtgag-30; Exon4-57, 50-gcggttgagcatcaggataa-30;
E1e-161, 50-ggtgtctaatcggtggctct-30; E1f-164, 50-tgtgttgaaa
ggatctgtcaagct-30 (underscored base pairs are speciﬁc
to the ﬁrst bases in exon 3 to guarantee speciﬁcity to
exon 1f–exon3 mRNA; this was ensured by the inability
of ampliﬁcation of plasmid-containing exon 1e under the
applied PCR conditions (data not shown)). Primers in Tbp
and Actb were Tbp-60, 50-agagagccacggacaactg-30; Tbp-
61, 50-actctagcatattttcttgctgct-30; Actin-165, 50-acacagtgct
gtctggtggt-30; Actin-166, 50-ctggaaggtggacagtgagg-30.
PCR conditions consisted of an initial melting step of
958C for 10min, and then ampliﬁcation was conducted
through 40 repetitions of a 958C step for 15s and a com-
bined annealing and extension step at 608C for 30s. In
case of amplicon E1f-E4, the annealing/extension step
was at 628C. Lack of unspeciﬁc ampliﬁcation was ensured
with a ﬁnal melting curve analysis from 558Ct o9 5 8C.
5’ RACE
50 Rapid ampliﬁcation of cDNA ends (50 RACE) was done
utilizing the SMART
TM RACE kit (Clontech) following
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from tumor 1161, uninfected BALB/c bone marrow and
brain were reverse transcribed with PowerScript
TM
Reverse Transcriptase using an oligo(dT) primer during
each SMART RACE reaction. 50 RACE PCR was subse-
quently done on 1/120 of the cDNA (corresponding to
8ng total RNA) with the PCR conditions: 5min initial
melting step at 958C, then 6 cycles of annealing step-
touch-down from 74 to 688C followed by 30 cycles of
ampliﬁcation with annealing temperature at 678C and a
ﬁnal 10min elongation step. Each ampliﬁcation cycle con-
sisted of a 30s melting step, 30s annealing step and 30s
elongation at 728C. Primers were a mixture of linker-
speciﬁc (UPM) forward primers (comes with the kit)
and either of the gene-speciﬁc reverse primers Exon3-96
(50-gcatctggctgcagcgactttgt-30), Exon3-46 (50-gcagaaactctg
tgcgttccttcttc-30) or intron2-86 (50-cgattagacaccatgggtggaa
ctgagc-30). The transcription start site (TSS) distribu-
tion in tumor tissue was similar when using either exon
3-speciﬁc reverse primer, and hence the TSS data were
pooled. A control reaction was carried out with a reverse
primer in Actb (Actin-104, 50-ctggaaggtggacagtgagg-30).
With regard to bone marrow and brain, a nested
PCR was done subsequently with forward and reverse
primers NUP (comes with the kit) and Exon3-97 (50-gctg
cagcgactttgttctt-30), respectively. Of each 50ml5 0 RACE
PCR, 2ml was cloned into pCR4 using the TOPO TA
cloning kit (Invitrogen) and transformed into One
Shot TOP10 competent cells (Invitrogen). Bacteria were
selected on ampicillin and screened for insert using
TEMPase Hot Start DNA Polymerase (Ampliqon) with
vector primers M13-110 50-gtaaaacgacggccag-30 and
M13-111 50-caggaaacagctatgac-30. The same primers
were used for sequencing PCR products from positive
colonies on an ABI3130 capillary sequencing set-up
(Applied Biosystems) using BigDye 3.1 chemistry
(Applied Biosystems).
Northern blotting
Ten mg total RNA from tumor samples were separated on
a formaldehyde denaturating agarose gel in a morpho-
lino–propane sulphonate (MOPS) buﬀer and capillary
transferred onto a ZetaProbe membrane (Bio-Rad) in
10  SSC for  12h. An exon 3–exon 4 Jdp2 probe gener-
ated by PCR using primers Exon3-47 (50-ctagacgaggaag
aagagcgaag-30) and Exon4-50 (50-tactacctggtttggcacctct
ctg-30) was randomly labeled with [a-
32P]dATP and used
for hybridization at 658C in a 0.25M sodium phosphate
buﬀer/7% SDS, and washed in 0.1  SSC/0.1% SDS.
Membranes were ﬁnally developed after being exposed
to Konica X-Ray AX medical ﬁlms (Santax Medico) for
an appropriate time.
Protein extraction and western blotting
Total protein was extracted on ice from  20mg tissue in a
radioimmunoprecipitation assay buﬀer (50mM Tris–HCl
pH 8, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS) complemented with 1mM PMSF and
complete Mini, EDTA-free (Roche) protease inhibitor
cocktail using a glass homogenizer. Samples were brieﬂy
subjected to sonication, incubated on ice for 30min and
protein collected after centrifugation for 30min at
13000 g. Total protein concentrations were determined
according to a bovine serum albumin standard curve using
the BCA kit (Pierce). Forty (tumor samples) or 25 (tissue
samples)mg protein were separated by 15% SDS–PAGE,
and electro-transferred onto a 0.2mMP
SQ polyvinylidene
ﬂuoride (PVDF)-membrane (Millipore). Membranes were
blocked at room temperature in TBS (20mM Tris–HCl,
200mM NaCl pH 7.6) containing 5% (w/v) fat-free milk
for 1h, incubated with a primary antibody overnight at
48C in TBS-T (TBS with 0.05% Tween-20) containing 5%
(w/v) fat-free milk (polyclonal anti-Jdp2, 1:1200 dilution,
and anti-b-Actin (I-19), 1:6666 dilution Santa Cruz
Biotechnology, sc-1616) or TBS-T (monoclonal anti-
Jdp2, 1:500 dilution, and monoclonal anti-H2B, 1:5000
dilution), washed three times in TBS-T, incubated with a
secondary antibody for 45min at room temperature in
TBS-T with 5% fat-free milk (goat anti-rabbit IgG-
HRP, 1:10000 dilution, Santa Cruz Biotechnology sc-
2004; rabbit anti-goat IgG-HRP, 1:5000 dilution, Santa
Cruz Biotechnology sc-2768; rabbit anti-mouse IgG-
HRP, 1:2000 dilution, DAKO P0260) and ﬁnally washed
three times in TBS-T. Membranes were developed using
ECL PLUS Western Blotting Detection System (GE
Healthcare) and exposed to medical ﬁlm (Konica X-Ray
AX medical ﬁlms Santax Medico). After Jdp2 detection,
the membranes were stripped in 25mM glycine–HCl pH 2,
1% SDS for 15min and washed several times in TBS
before being immunoblotted with an anti-b-Actin anti-
body. Rabbit polyclonal anti-Jdp2 serum was kindly pro-
vided by Dr A. Aronheim, Haifa, Israel (1). The
monoclonal antibodies were isolated from hybridoma
cell lines J#176-3.2 and J#249-1.1, kindly provided by
Dr K. Yokoyama, Ibaraki, Japan (6), using the Nab
spin kit (Thermo Scientiﬁc).
Vectors
For transient transfections, PCR fragments of Jdp2
full length and isoforms ORFs were cloned into a
pSG5-modiﬁed pSG5-FLAGnt vector using restriction
enzymes XhoI and BamHI. Cloning fragments were gen-
erated using forward primers wt-66 (50-ggggctcgagatgatgcc
tgggcagatc-30), 132-64 (50-ggggctcgagatgtgggtgagaaaggg
ggat-30), 119-65 (50-ggggctcgagatgtgtcaggtgggaagctgt-30)
or 107-114 (50-ggggctcgagatggagtggtgtgtgttga-30) and
reverse primer jdp2stop-67 (50-ccccggatcctcacttcttgtccagct
gctcca-30). For transduction experiments, PCR fragments
were made using appropriate Jdp2 pSG5-FLAGnt vectors
as template with forward primer p231-143, 50-atcgtatgcgtc
tcccatggactacaaagacgat-30 and p231-jdp2-145, 50-atcgtatgg
acattgctcacttcttgtccag-30 and inserted into the bicistronic
vector AKV-neo-IRES (29). PCR fragments for human
NRAS and human NRAS G12D were made using primers
p231-144, 50-atcgtatgccatggactacaaagacgatgacgataaaatgac
tgagtacaaactggtg-30, and p231-146, 50-atcgtatggacattgcttac
atcaccacacatg-30, on appropriate vectors carrying human
NRAS or NRAS G12D (kindly provided by Dr. Borja
Balları´n-Gonza ´ lez) and inserted into AKV-neo-IRES.
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Cell cultures and experiments
NIH 3T3 cells were grown in Dulbecco’s Modiﬁed Eagle’s
medium containing glutamax (Gibco) and supplemented
with 10% new born calf serum (Invitrogen) and 1% penin-
cillin–streptomycin. Localization studies were conducted
by growing NIH 3T3 cells on gelatin-coated glass cover
slips and transfecting them using Lipofectamine 2000
(Invitrogen). Cells were then ﬁxed in 4% para-formalde-
hyde/PBS at room temperature for 10min, washed in PBS
and permeabilized in 0.2% Triton X-100/PBS at room
temperature for 10min. After two washes, cells were left
in a blocking solution (0.1% Tween-20/3% BSA/PBS) for
1h at room temperature. Then, cells were incubated with
an anti-FLAG monoclonal antibody (1B11, 1:400 dilu-
tion) in the blocking solution for 1h at room temperature
and washed three times in 0.1% Tween-20/PBS. Finally,
cells were incubated sheltered from light with a TRITC-
conjugated secondary antibody (1:500 dilution) in the
blocking solution for 1h at room temperature before
being washed three times in PBS containing 0.1%
Tween-20, and two times in PBS. Cover slips were
mounted on object glasses using the ProLong antifade
mounting solution with DAPI (Invitrogen), and kept
at 48C in dark until analyzed on a Zeiss Axiovert M200
ﬂuorescence microscopy within 24h.
For cell-growth inhibition analysis, NIH 3T3 cells were
transfected as described above and grown for 24h post-
transfection before culturing in puromycin (2.0mg/ml)
for 3 weeks.
Soft agar assay was done by transducing NIH 3T3
cells at a multiplicity of infection (m.o i.) of 1 with
AKV-neo-IRES expressing the indicated protein 36h
before seeding 4.2 10
4 into 10cm
2 dishes. Cells were
seeded onto a 0.6% bottom layer [complete medium
including 0.6% LMP agarose (NuSieve)] and grown in
0.5% top layer for 2 weeks. From each dish, 100 pictures
were taken by a Leica DFC 300 FX microscopy and the
number of colonies larger than 200mm were counted using
in-house developed software (30).
RESULTS
Integrations into Jdp2
Genomic DNA from tumors induced by SL3-3 murine
leukemia virus in 1767 newborn BALB/c mice was
isolated and the host-provirus DNA PCR ampliﬁed and
sequenced. Results from this cohort have previously been
published (26,31–33). We wanted to look for integration
loci in which the distributions of insertions could indicate
novel transcriptional structures and focused on the Jdp2
locus, which is targeted by retroviral insertions in 125
(7%) individual animals (Figure 1A). The locus has pre-
viously been described as being an insertional target in
murine T-cell lymphomas induced by Moloney MLV
(17,19,20) and SL3-3 MLV (18). Retroviral integrations
within this locus appeared in clusters, here abbreviated
clusters A through F, of which B, D and F were
predominant in terms of density and frequency of integra-
tions. Cluster A, B and C were positioned upstream of
Jdp2 predominantly in the opposite transcriptional orien-
tation whereas cluster E was positioned downstream of
Jdp2. Cluster F consisted of positively orientated pro-
viruses in or near the 30 UTR in exon 4. In this study,
our focus was drawn in particular to cluster D consisting
of 25 integrations in the 30 end of intron 2 of the Jdp2
gene. The predominant inverse transcriptional orientation
of the proviruses as compared to Jdp2 suggested a retro-
viral enhancer activation of a cellular promoter situated in
the 30 end of the integration cluster. The notion was fur-
ther strengthened by the positive orientation of a few inte-
grations in the 30 end of cluster D, which could be
indicative of promoter activation. To test for such a pro-
moter insertion mechanism of Jdp2 deregulation in tumors
carrying a positively orientated provirus within cluster D,
we did RT-PCR with primers in the viral U3 region and
Jdp2 exon 3 and 4 on tumor cDNA. We indeed found
chimeric transcripts consisting of viral and Jdp2 sequences
in four out of twenty tumors including one already iden-
tiﬁed by the initial retroviral tagging (tumor 1363)
(Figure 1B). A similar result although at a much higher
frequency was found recently by Stewart et al. (20).
To estimate the frequency of cluster D insertions, we
performed directed PCR on control tumors in which no
Jdp2 locus integrations were found by retroviral tagging
using virus LTR-speciﬁc primers and an exon 3 reverse
primer. From this we estimated the frequency of integra-
tions into cluster D to be as many as 25% implying
subclonality with regard to cluster D insertions, a notion
supported by the fact that some control tumors show
elevated expression of Jdp2 (see below). Again we found
predominant integrations in the opposite orientation as
compared to Jdp2. No cluster D insertions in either direc-
tion were found in tumors from BALB/c mice infected
with the B-cell lymphomagenic Akv MLV signifying the
relevance of retroviral Jdp2 intron 2 insertions speciﬁcally
in T-cell lymphomagenesis (data not shown).
Intragenic integration into Jdp2 correlates with the
high expression level of mRNA species including
Jdp2 intron 2 sequences
We tested for expressional deregulation of Jdp2 in tumors
with MLV insertions within the Jdp2 locus by northern
blotting using a probe covering exon 3 and part of exon 4
(Figure 2A). The northern blot analysis included tumors
with integrations into cluster D and cluster B (upstream of
Jdp2 in opposite orientation), as well as some randomly
selected control tumors in which no integration in the Jdp2
locus was detected by the retroviral tagging protocol.
In both cluster B and cluster D tumors, the mRNA level
of the neighboring genes cFos and Batf were less than
three times higher than that observed in control tumors
as assessed by quantitative RT-PCR (QRT-PCR)
(Figure S1 and data not shown), and hence we conclude
that these genes are not targeted by insertions. This is in
agreement with the conclusions reached previously by our
group (18) and by Hwang et al. (17) using SL3-3 MLV and
Moloney MLV, respectively. Consistent with previous
4660 Nucleic Acids Research, 2009, Vol. 37,No. 14results, upregulation of Jdp2 mRNA was observed as
compared to control tumors in most cases. However, we
note that some tumors with proviral integration into the
Jdp2 locus have no Jdp2 upregulation, which could be
attributed to tumor sample heterogeneity with many sub-
clonal Jdp2 integrations as mentioned above. The size of
the detected Jdp2 mRNA was consistent with the pub-
lished species (1.5–1.7kb, see Table 1) (Figure 2B and
C). Strikingly, we observed in several cluster D tumors
upregulation of small Jdp2 sub-species of which an
 1.3kb species was the most common (Figure 2B).
These subspecies were not observed in the tumors with
integration into cluster B (Figure 2C). We also note
expression of larger mRNA species in some tumors.
To investigate whether the observed 1.3kb Jdp2 mRNA
isoforms in cluster D tumors were generated by tran-
scription from intron 2 as suggested by the integration
distribution, we measured the level of canonical versus
intronic Jdp2 mRNA (amplicon E2-E3 and I2-E4, respec-
tively, in Figure 2A) with quantitative real-time PCR
(QRT-PCR) on a panel of cluster B and cluster D.
Tumors without known integrations in the Jdp2 locus as
found by retroviral tagging were included as controls
(Figure 2D and E). Six out of nine cluster B tumors had
>10 times the amount of exon 2–exon 3 Jdp2 mRNA
found in control tumors (Figure 2D, bottom). In general
accordance with the northern blot, increased mRNA levels
were not observed in tumors 959, 150 and 1534. In half of
the cluster D tumors (tumors 474, 978, 1908 and 1161), a
5- to 8-fold increase of exon 2–exon 3 mRNA was
observed as compared to the controls. In the remaining
tumors, mRNA levels were comparable to control tumors
(Figure 2D, top). With regard to intronic transcription, an
opposite pattern was observed (Figure 2E). Only one clus-
ter B tumor (tumor 645) appeared to have an increased
amount of intron 2–exon 4 mRNA as compared to control
tumors (Figure 2E, bottom), while ﬁve cluster D tumors
(tumors 474, 1571, 1833, 1908 and 1161) had 4–45 times
higher levels of intronic mRNA (Figure 2E, top). In tumor
978, the high levels of Jdp2 sub-species observed by north-
ern blotting (Figure 2B) was not reﬂected by amplicon
I2-E4 ampliﬁcation (Figure 2E, top) suggesting a more
complex transcriptional structure of Jdp2. Taken together,
these data indicate increased transcription of sequence
in the 30 end of intron 2 in tumors harboring intron 2
retroviral integrations (cluster D integrations) compared
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integration outside the Jdp2 locus.
A complex transcriptional structure resides within
intron 2 of Jdp2
Two immediate explanations can account for the expres-
sion of mRNA including the 30 end of Jdp2 intron 2.
One possibility is that transcription starts upstream of
exon 2 and utilizes a cryptic splice acceptor site in the 30
end of intron 2. An alternative hypothesis would invoke
the existence of alternative promoters within intron 2.
We tested for alternative splice donor sites with PCR
on cDNA from a range of tumors using forward primers
situated in upstream Jdp2 exons together with reverse pri-
mers in the 30 end of intron 2. However, we repeatedly
failed to ﬁnd cDNA representing alternative splicing
between any of the four possible exons 1 (supported
by transcription data on http://genome.ucsc.edu/) and
the 30 end of intron 2 (data not shown).
To search for a possible novel transcription start
site immediately upstream of exon 3, we performed 50
RACE on RNA from tumor tissue. We used the tumor
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Figure 2. Correlation of intragenic provirus insertion and appearance of Jdp2 intron 2 including transcripts. (A) Schematic representation of the
localization of the Northern blot probe and QRT-PCR amplicons E2-E3, E2-E4, I2-E4, E1e-E4 and E1f-E4 for Jdp2 mRNA detection with exons
shown as boxes and coding sequence in black. (B and C) Northern blotting on total RNA from thymus tumors from a subset of animals with
integration in clusters D (B) and B (C) according to the retroviral tagging data. Control samples (Ctrl) are thymic tumors from retrovirus-infected
animals of the same cohort in which no integrations were found by retroviral tagging. The distance between integration and the beginning of Jdp2
exon 3 for each tumor is shown above the lanes. Ethidium bromide staining of ribosomal bands 28S and 18S was used to evaluate even loading and
RNA integrity. (D and E) QRT-PCR on a subset of D tumors and B tumors amplifying either Refseq Jdp2 mRNA (E2-E3) (D) or intron 2-including
alternative mRNA (I2-E4) (E). The signal was normalized to Tbp and shown as fold diﬀerence to the average of control tumor samples (Ctrl).
4662 Nucleic Acids Research, 2009, Vol. 37,No. 14sample identiﬁed as having the highest level of intron 2
containing mRNA among the tumors as determined by
QRT-PCR (tumor 1161, 45-fold higher as compared to
control tumors, see Figure 2E). In addition, we performed
50 RACE on RNA from bone marrow (BM) and whole
brain tissue from uninfected BALB/c mice. During SL3-3
MLV infection of newborn mice, BM cells are a likely
reservoir for early integration events whereas brain
tissue is unrelated to infection. 50 RACE PCR on tumor
tissue was done with either of three reverse primers (oligo
86 locates in intron 2, and oligo 96 and 46 are speciﬁc to
exon 3), whereas 50 RACE on BM and brain tissue was
done using a single primer (oligo 96) (see Figure 3). As a
control, 50 RACE PCR was done with a reverse primer in
the 50 end of the gene for  -Actin (Actb). PCR products
were cloned and between 50 and 100 bacterial colonies
from each 50RACE PCR representing individual tran-
scription start sites (TSS) sequenced. The result of the
analysis is summarized in Table 1. As expected, 50
RACE PCR for Actb yielded a sharp band in agreement
with a single predominant transcription initiation site
(Figure 3A, lane 5). In contrast, we always detected
smeared bands in both the Jdp2 intron 2 and exon
3-speciﬁc 50RACE PCRs suggesting existence of multiple
50 ends for the intron 2 including mRNA species
(Figure 3A, lanes 2–4).
When using an intron 2-speciﬁc 50 RACE PCR on
tumor tissue we found several TSSs within a 110 nucleo-
tide window located  150 base pair upstream of exon 3.
Transcripts from this region all continue without splicing
into exon 3 giving rise to mRNA species with an alterna-
tive intron 2-derived 50 terminus in place of the normal
exon 1 and exon 2 of Jdp2 (corresponding to exon 1e
in Figure 3B).
TSSs cloned from the exon 3-speciﬁc 50 RACE PCR
identiﬁed the same 110 window as found above. In addi-
tion, a variety of transcripts utilizing intron 2 splice donor
sites and the canonical exon 3 splice acceptor site were
identiﬁed. The transcripts were denoted exons 1e, 1f, 1g,
1h, 1i, 1j and 1k based on their splicing structure (Table 1
and Figure 3B and 3C). Two less abundant initiation sites
upstream of the major initiation sites in exon 1e
(brain tissue) and 1f (bone marrow) were denoted 1e-2
and 1f-2, respectively. We reserve the terms exons 1a
through 1d for the four alternative exons 1 that currently
are supported by public transcript records (http://genome
.ucsc.edu/), and which are all situated outside the region
considered here (see Table 1). While exon 1k was exclu-
sively observed in tumor tissue, exon 1j, situated in intron
2 almost 10kb upstream of exon 3, was found only in
normal tissue (brain). The far most predominant tran-
scripts in all three tissues were exons 1f and 1e accounting
for 74% (tumor tissue), 88% (brain) and 98% (bone
marrow) of all transcripts. Since the translation initiation
codon of Jdp2 is encoded by exon 2, the alternative sub-
species identiﬁed here could produce protein isoforms with
an altered N-terminus. Interestingly, a methionine codon
in frame with Jdp2 was present in exons 1e, 1f and 1i from
tumors as well as in exon 1j from brain (Figure 3B and C).
Transcription from exon 1e may give rise to either a
132-amino-acid isoform, Jdp2-132, or, using a second
methionine codon, a 119-amino-acid isoform, Jdp2-119.
Transcription from exons 1f, 1i and 1j generates Jdp2 iso-
forms of 107-, 98- and 117-amino-acid, respectively. In
this line, it should be noted that exon 2 of Jdp2 encodes
a protein domain responsible for the inhibition of histone
acetylation (7). Except for one sequence (a brain exon 1e
sequence), exon 1e and exon 1f TSS tags from normal
tissue are situated 30 to the methionine codons and
hence cannot give rise to Jdp2-132/119 or Jdp2-107 pro-
duction. Transcription in tumor tissue, in contrast,
initiated close to the integrated provirus and mostly
upstream of the positions found in normal tissue.
Thereby, the provirus-activated transcripts disclose
upstream Jdp2-in-frame methionine codons (compare
exons 1e and 1f in Figure 3B with Figure 3C).
Figure 3D summarizes the diﬀerent predicted protein
structures.
In support of our data, we note that all eight diﬀerent
TSS positions identiﬁed in uninfected tissue had a
Table 1. Features of murine Jdp2 exons 1
Exon
a Coordinate
b Size (bp) Transcription initiation
c Splice donor sequence
c
1a 86488519 199 gccacagcctGCGGGAGGGA CTTCTGCACGgtgggttcac
1b 86488208 123 gggagccgcgGGCGGGGCGC GGAGGTGAAGgtcagtgggt
1c 86489121 65 aaccaacaggGCTTCCTTCG ATATAAGAAGgtaagcaggc
1d 86491329 85 ctctgtagaaGACATCTTTC AGCCAAAGAGgtaaaagata
1e 86520704 149 agctgtgctcAGTTCCACCC TCTGCAGAGGgtgagtgggg
1e-2 86520617 236 tctccgactcAGCAGTCACA TCTGCAGAGGgtgagtgggg
1f 86519979 23 atggagtggtGTGTGTTGAA ATCTGTCAAGgtaagcagga
1f-2 86519976 26 agaatggagtGGTGTGTGTT ATCTGTCAAGgtaagcagga
1g 86520512 116 agccccagatATTCTGGCTG GCAGTCACAGgtgtttgctg
1h 86520110 76 gtcttgctttATGAGTCCTG GTCCATCCAGgtgagaaggc
1i 86520625 22 tcagcagtcACAGGTGTTTG TGAGATGTGGgtgagaaagg
1j 86511034 274 tcctggttctGCAGACAGCA AGGGCCAAGGgtgagttcag
1k 86520513 128 gccccagataTTCTGGCTGA TTGCTGAGATgtgggtgaga
aData on exons 1a (RefSeq NM_030887), 1b (mRNA bc019780), 1c (mRNA ab034697) and 1d (EST by317195) are based on UCSC mm 8 February
2006. Minor secondary TSSs found for exons 1e and 1f are denoted 1e-2 and 1f-2, respectively. Exon 1k was only identiﬁed in tumor tissue.
bPosition on chromosome 12 of the transcription start site according to UCSC mm8 February 2006.
cExon sequence is in capital case.
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tion start site positions (CpA, TpA or TpG in Table 1),
in line with the accepted view on the initiator motif (Inr) in
mammalian polymerase II transcribed genes (34,35). In
tumor tissue, 32% of the cloned TSSs were non-PyPu
dinucleotides as exempliﬁed in exon 1k (Table 1 and
data not shown).
We conducted a bioinformatic analysis to look for
cis-regulatory elements in 1200 base pairs covering the
region between 300bp 50 to the TSS of exon 1f and exon
3 using the DiAlign software (36) (Figure S2). The region
is not conserved between mammals and avian species since
the similarity between mouse and chicken was conﬁned
to the exon 3 sequence (data not shown). As would be
expected, the relative conservation score is generally
higher when only including mouse and rat; larger patches
(50–150bp) of diﬀerences exist in chimpanzee (insertion),
dog (insertion) and cow (insertion and deletion) and in
human, chimpanzee, macaque, cow and dog as a group
(insertion) as compared to mouse and rat (data not
shown). Despite this, minor peaks of conservation
when considering all species are found around the tran-
scriptional initiation regions of exons 1e, 1f and 1g
(Figure S2). When only considering mouse and rat, con-
servation peaks are seen on all the transcription start sites
of the alternative exon 1s in the region (Figure S2). Other
potential start sites of transcription or regulatory modules
such as enhancers or splice regulatory sequences may
reside within peaks of conservation, which are not over-
lapping the TSSs found here. To this end, we used
MatInspector to identify possible conserved transcription
factor-binding motifs within the considered regions (37)
(Figure S3–S5). The regions indeed have several conserved
transcription factor motifs including binding sites for
SP1, YY1 and ETS factors. We note the absence of obvi-
ous conserved TATA-box sequences within the sequence
immediately in front of the TSS sequences.
Jdp2 protein isoforms are expressed in T-cell tumor
tissue and normal tissue
The identiﬁcation of multiple mRNA forms with the
potential to encode for novel protein isoforms of Jdp2
prompted us to investigate mRNA levels of the abun-
dantly found alternative transcripts 1e-3-4 and 1f-3-4 in
comparison with Jdp2 protein levels. QRT-PCR speciﬁc
for exon 1e and speciﬁc for the splicing between exons 1f
and exon 3 was done with amplicons E1e-E4 and E1f-E4,
respectively (Figure 2A). Amplicon E1e-E4 lies down-
stream of the two AUG codons and thus does not distin-
guish the longer and shorter 1e exons (exons 1e-2 and 1e
in Table 1). Figure 4A–C shows the results from some of
the most diﬀerentially expressed tumor samples as com-
pared to the normal thymus expression (set to 1). Of the
three cluster D tumors (763, 1363 and 1161), tumor 763
had >100-fold increased levels of the canonical wild-type
transcript similar to the cluster B tumors (20 and 181)
(Figure 4A). As suggested by northern blotting
(Figure 2C), control tumor 1046 also displayed highly
increased wild-type levels. PCR using virus and cluster
D-speciﬁc primers in tumor 1046 in fact detected integra-
tion into cluster D while the proviral status of cluster B
was not investigated. Levels of the 1e-3-4 RNA were >50
times higher in the three cluster D tumors and tumor 1046,
whereas cluster B tumors only displayed a moderate
increase ( 10-fold) as compared to control thymus
B
-103
-808
1f
1h
1g
1i
1k
1e
M
M
*
*
M
*
MM
-747
-563
-121
-107
wt exon 3
96 46 86 provirus
Tumor tissue
1j
1f
1h
1g
1i
1e
M
wt
M
-9441
-747
-121
*
*
M
exon 3
-563
-103
96 Normal tissue
*
C
1a-1d/Jdp2
1 68 102 163
MM MM M
INHAT DBD ZIP
1e/Jdp2-132 MWVRKGDLSPCLSMCQVGSCAQFHPWCLIGGSVPSQ MM
37 132
1e/Jdp2-119 MCQVGSCAQFHPWCLIGGSVPSQ MM
24 119
1f/Jdp2-107 MEWCVLKGSVK MM
12 107
1i/Jdp2-98 MW MM
39 8
1j/Jdp2-117 MKLPVLWREPRRVESSTAGPR MM
22 117
D
1
1
1
1
1
A
4
500 −
400 −
300 −
200 −
123 M 5
H2O
96
46
86
β-Actin
Figure 3. Identiﬁcation of Jdp2 intron 2 mRNAs. (A) Ethidium bro-
mide-stained agarose gel showing representative PCR products with
linker-speciﬁc forward primer on 50 RACE cDNA from tumor 1161
using diﬀerent reverse primers in Jdp2 (oligos 96, 46 and 86, lanes 2, 3
and 4, respectively) and Actb exon 3 (lane 5); in lane 1 no cDNA
template was added. (B) and (C) Schematic structure of the alternative
Jdp2 exon 1e through 1k as found by 50 RACE in tumor tissue (B) and
normal tissue (C). Positions of exon 1-speciﬁc splice donor sites relative
to exon 3 are given in base pairs. Putative start codons (M) in frame
with the ORF of Jdp2 are indicated, while an asterisk indicates that no
ORF is present in frame with Jdp2. (D) Protein structure of Jdp2 as
generated from exon 1a through 1d, and predicted Jdp2 isoforms gen-
erated from exon 1e, 1f, 1i and 1j. The INHAT domain as well as the
basic DNA binding domain (DBD) and the leucine zipper (ZIP) regions
are indicated. Methionines are indicated (M) and the N-terminal pep-
tides are shown for the isoforms.
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>1000-fold higher in tumors 1363 and 1161 while between
50 and 150 times higher in tumors 763, 20, 181 and 1046
as compared to control thymus.
Jdp2 protein levels in the same tumor samples were then
investigated by western blotting using a rabbit polyclonal
anti-Jdp2 protein (Figure 4D, top). The relative signal of
full length Jdp2 ( 20kDa) between tumors corresponded
to the relative exon 2-3 mRNA levels. Smaller bands
(at  17 and 14kDa) were detected in all samples except
control tumor 1980 with the highest signal in tumors 763
and 1161. To conﬁrm that the smaller bands represent
alternative Jdp2 isoforms, the same protein samples
were subjected to a separate SDS–PAGE immunoblot
using Jdp2 murine monoclonal antibodies (Figure 4D,
bottom). Full-length Jdp2 was readily detected in the
same samples as when using the polyclonal antibody.
Further, in samples 763 and 1161, a band corresponding
to the lower 14kDa Jdp2 isoform was evident as was,
although more weakly, the 14kDa band in sample 20
and the 17kDa band in samples 763, 1161 and 1046.
Tumor 1363 is a special case in which the provirus is
transcriptionally orientated similar to Jdp2. This allows
for the formation of chimeric spliced or unspliced
mRNAs containing viral sequences, which may have an
impact on the ratio between levels of protein isoforms and
RNA (compare Figure 4B and C with D for tumor 1363).
Together with the mRNA expression data, these data
support the notion of the expression of Jdp2 isoforms
in T-cell tumor tissue.
We next analyzed the expression level of canonical Jdp2
and truncated Jdp2 in a panel of tissues from BALB/c
mice not infected with MLV. In order to minimize eﬀects
from sample heterogeneity, relative expression signal was
normalized to the geometric mean of Actb and Tbp (28)
(Figure 5A–C, black bars). In some cases, this had a dra-
matic eﬀect on the relative expression level as compared to
normalization to total RNA (38,39) (Figure 5B, gray
bars), as is evident, for instance, for amplicon E1e–E4 in
testis and brain. The following is based on interpretation
using Tbp and Actb normalizations. Full-length Jdp2
mRNA was relatively highly expressed in the brain
and lung tissue, while an intermediate expression level
was seen in spleen, heart, bone marrow and kidney
(Figure 5A). The expression of exon 1e was relatively
highest in the brain (Figure 5B), while exon 1f was most
prominently expressed in heart tissue (Figure 5C). We also
estimated the absolute copy number of transcripts by
using standard curve generated from Jdp2 amplicon-con-
taining plasmids of known concentrations (see ‘Materials
and Methods’ section). Canonical Jdp2 E2-E4 was 6
(in testis) to 100 (in heart) times more abundant than
Jdp2 E1e-E4, and between 3 (in liver) and 400 (in lung)
times more abundant than Jdp2 E1f-E4 (data not shown).
Next, we did western blot analysis using a polyclonal anti-
Jdp2 antibody on tissue samples extracted from BALB/c
mice (Figure 5D). Immunoblotting against  -Actin and
histone H2B (a marker for nuclear content) was subse-
quently done to evaluate for protein loading. Highest
full-length Jdp2 signal was seen in the skeletal muscle
and, to a lesser extent, in testis, heart and liver. A smaller
band of similar size as the larger one seen in tumor
samples ( 17kDa) was most prominently observed in
heart although also in testis, liver and skeletal muscle.
Figure 4. Jdp2 isoforms are highly expressed in T-cell tumors. (A–C) QRT-PCR was done in triplicates on tumor tissues to detect full length (A),
exon 1e-3-4 (B) and exon 1f-3-4 (C) mRNA. Expression signal was normalize with Tbp and shown as fold diﬀerence to uninfected control thymus.
The ﬁgures are representative of two to three experiments. (D) Two separate western blot experiments using 0.2mM PVDF membranes were done on
crude protein extracts from the same tumors as in (A–C) using either polyclonal anti-Jdp2 antibody (#489) (top) or a mix of monoclonal anti-Jdp2
antibodies J176 and J249 (bottom). Membranes were subsequently immunoblotted using anti-b-Actin antibody. Open and closed arrows indicate
position of full length ( 20kDa) and isoform Jdp2 ( 14 and 17kDa), respectively.
Nucleic Acids Research, 2009,Vol.37, No. 14 4665In liver tissue, a protein of smaller size was evident. Using
monoclonal antibodies, however, we could only detect the
full-length Jdp2 in the skeletal muscle upon long exposure
time (data not shown). This may be due to the relatively
low expression level as compared to tumor samples with
integrations in combination with lower reactivity of
monoclonal antibodies. In summary, these data indicate
that Jdp2 intragenic MLV insertions upregulate Jdp2 iso-
forms from intron 2 promoters, which are active in various
non-infected murine tissues.
Jdp2 isoforms localize to the nucleus similar to
full-length Jdp2
Jdp2 localizes to the nucleus when expressed from a het-
erologous promoter speciﬁcally in the heart (15), yet any
nuclear localization signal remains undeﬁned. The Jdp2
isoforms identiﬁed here have the N-terminal part replaced
by a short peptide encoded by the various alternative
exons 1. To investigate the subcellular localization of
Jdp2 and to see if the Jdp2 isoforms had an altered local-
ization pattern, full length as well as Jdp2-132, Jdp2-119
and Jdp2-107 was cloned into a pSG5-derived vector,
pFLAGnt, and expressed in mouse ﬁbroblast as N-term-
inal FLAG fusion proteins. Protein localization was then
visualized by immunoﬂuorescence using an anti-FLAG
antibody. Full-length Jdp2 localized exclusively to
the nucleus (Figure 6A). The same localization was
observed for isoforms Jdp2-132, Jdp2-119 and Jdp2-107
(Figure 6B–E) whereas no signal was seen in cell trans-
fected with the same vector but without Jdp2 transgene
(Figure 6F). We note that in some Jdp2-132 transfected
cells, increased signal intensity was observed asymmetri-
cally near the nuclear rim (Figure 6B). This localization
pattern was not a consequence of high expression
of FLAG-Jdp2-132 as the proportion of cells with this
localization pattern was equal between high and low
level Jdp2-132 expressing cells.
Ectopic expression of Jdp2 and Jdp2 isoforms increase
tumorigenic potential of oncogenic NRAS G12D
The role of Jdp2 in apoptosis and cell cycle control is
subject to debate and seems to vary with cellular context
(10,12,13,21). To test if the cell growth inhibitory eﬀect
ascribed previously to full-length Jdp2 also was present
Figure 5. Jdp2 isoforms are diﬀerentially expressed in the normal tissue. (A–C) QRT-PCR was done in triplicates as described for Figure 5 on the
indicated BALB/c mouse tissues to detect full length (A), exon 1e-3-4 (B) and exon 1f-3-4 (C) mRNA. Expression signal is shown as normalized to
the geometric mean of Actb and Tbp (black bars) or normalized to total RNA (white bars) and is shown as fold diﬀerence to thymus. The ﬁgures are
representative of two–three experiments. (D) Western blotting on 0.2mM PVDF membranes using polyclonal anti-Jdp2 and, subsequently, anti-b-
Actin and anti-H2B antibody on crude protein extracts from the same panel of BALB/c tissue. Open and closed arrows indicate the position of full
length and isoform Jdp2.
4666 Nucleic Acids Research, 2009, Vol. 37,No. 14for the 132-, 119- and 107-amino-acid isoforms we trans-
fected NIH3T3 cells with the respective expression vectors
and added puromycin 24h post-transfection to select
for the capacity to form colonies. Whereas we readily
observed colonies among cells transfected with the
empty plasmid (pFLAG), cells transfected with Jdp2,
Jdp2-132, Jdp2-119 or Jdp2-107 died (Figure 7A).
Importantly, the ectopic expression level was several
orders of magnitude higher than that observed in the
tumor samples (Figure S6). Thus, Jdp2-mediated cell
growth inhibition under these conditions is not only
restricted to the full-length Jdp2 isoform but is also evi-
dent for protein isoforms lacking the N-terminal INHAT
domain.
Since full-length Jdp2 has been reported to inhibit
RasV12-induced focus formation (21), we tested the
eﬀect Jdp2 and Jdp2 isoforms on anchorage-independent
growth in the context of human NRAS and oncogenic
NRAS G12D. In order to minimize possible apoptotic
eﬀects observed in Figure 7A, Jdp2, Jdp2-119 and
Jdp2-107 was expressed from an internal ribosomal
entry site (IRES) within the LTR-driven retroviral
vector AKV-Neo-IRES. Figure S7 demonstrates that
the transduced cells exhibit moderate over-expression as
compared to endogenous full-length Jdp2, while a more
prominent over-expression was observed under the transi-
ently expressing conditions used in Figure 7A. NIH 3T3
ﬁbroblasts co-transduced with a retroviral vector expres-
sing NRAS and a retroviral vector expressing Jdp2 or
either isoforms did not sustain colony growth signiﬁcantly
diﬀerent from the NRAS-expressing vector alone when
seeded in a complete medium supplemented with 0.5%
agar (Figure 7B). Expression of Jdp2, Jdp2-119 or Jdp-
107 alone also did not result in colony formation signiﬁ-
cantly diﬀerent from either mock transduction or NRAS
transduction (data not shown). In contrast, when we
co-transduced NRAS G12D together with either Jdp2
forms, a signiﬁcant increase of  50% in colony formation
was seen as compared to NRAS G12D alone (P<0.05,
two-tailed Student’s t-test) (Figure 7C). Thus, both Jdp2
proteins with and without the N-terminal part harboring
the INHAT activity can increase transformation by onco-
genic NRAS G12D but not NRAS.
DISCUSSION
Here, we have described the identiﬁcation of a novel
region within the second intron of the AP-1 repressor
A Jdp2 132 119
107 H2O vec
C
Colonies> 200μM
Colonies> 200
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*
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Figure 7. Phenotypic eﬀects of ectopic expression of Jdp2 isoforms.
(A) NIH3T3 cells were transiently transfected with vectors expressing
N-terminally FLAG tagged full length Jdp2 or either of three
N-terminally Jdp2 isoforms, Jdp2-132, Jdp2-119 or Jdp2-107. Twenty-
four hours after transfection, cells started growing in a selective
medium containing puromycin. Three weeks later, the cells were ﬁxed
in methanol and colonies stained with methylene blue. The results are
representative of two independent experiments, each done in duplicate.
(B and C) NIH 3T3 cells were co-transduced with the indicated vectors
(m.o.i.=1) 48h before being seeded in the medium supplemented with
0.5% agar. After 2 weeks of growth, 100 pictures per dish were taken,
and the number of colonies larger than 200mm were counted. Error
bars indicate the standard error of the mean from four independent
experiments of which representative pictures are shown. The black scale
bar—insert in each pictures—corresponds to 500mm. A signiﬁcant dif-
ference (P 0.05) to ‘G12D + Vector’ by two-tailed Student’s t-test is
shown with an asterisk.
A D
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Figure 6. Jdp2 isoforms localize to the nucleus. NIH3T3 cells were
transiently transfected with vectors expressing N-terminally FLAG
tagged full length Jdp2 (A) or either of three N-terminally Jdp2 iso-
forms, Jdp2-132 (B-C), Jdp2-119 (D) or Jdp2-107 (E). As controls are
shown cells transfected with empty vector (F). The subcellular localiza-
tion was revealed by immunocyotchemistry using an anti-FLAG
primary antibody (left). Cells were co-stained with DAPI dye (right).
The results are representative of three independent experiments.
Nucleic Acids Research, 2009,Vol.37, No. 14 4667Jdp2 from which several alternative mRNA species are
expressed in T-cell lymphomas of mice and in normal
tissue. Some, but not all, of the alternative mRNAs
encode for protein N-terminal isoforms of Jdp2.
The existence of intragenic promoter activity could be
hypothesized from the distribution of retroviral integra-
tions in the Jdp2 locus as found by retroviral tagging on
T-cell tumors induced by SL3-3 MLV in 1767 mice. When
integrated in opposite transcriptional orientation of the
proto-oncogene being activated the provirus is typically
situated upstream of the cellular promoter. This mecha-
nism has been termed ‘enhancer activation’ and is exem-
pliﬁed by activation of Gﬁ1 (17,40), Rras2 (41,42) and
Rasgrp1 (20,24) in various models (data from (43)), as
well as integration clusters A, B and C reported here
and elsewhere (17,18). By analogy, oppositely orientated
proviruses within the transcriptional unit of a cellular gene
such as cluster D in Jdp2 may reveal novel promoters 30 to
the integrations. A recent publication from our group on
insertional activation of Bach2 in B-cell lymphomas (44),
as well as unpublished data, indicates a more general phe-
nomenon of proviral activation of ‘hidden’ intragenic pro-
moters, and we propose that large-scale transcription start
site mapping in provirally targeted genes will contribute in
ﬁnding new structures of already known cancer genes.
Using existing retroviral tagging data such as from
RTCGD (43) additional promoter regions are envisioned
to be identiﬁed. It would be of interest to investigate
whether such alternative transcripts have a regulated
expression in normal tissue, as in case of Jdp2, or require
cis-regulatory elements such as from provirus insertion or
chromosomal translocation.
It is now evident that the transcriptome of higher mam-
mals is far more complex than earlier anticipated (45–50).
A signiﬁcant contribution to increased transcriptional
complexity comes from the usage of alternative promoters
and accordingly ﬁrst exons among polymerase II tran-
scribed genes (34,51–53). Current database records
(http://genome.ucsc.edu/) support the existence of four
non-overlapping initiating non-coding exons of Jdp2
that splice to a common splice acceptor site in exon 2
(exons 1a–1d in Table 1), although it should be kept in
mind that the precise transcription start sites of exons 1a,
1b and 1d await ﬁnal veriﬁcation. The novel Jdp2
transcript structures identiﬁed here within intron 2 add
to the complexity of Jdp2 transcriptional regulation.
All lack TATA-box consensus elements surrounding the
30bp upstream regions from the TSS. This result is not
unexpected according to recent transcriptome analyses
showing that the presence of TATA-box sequences is an
exception rather than a rule and that numerous alternative
initiation sequences must exist (34,54–56).
The transcripts including Jdp2 intron 2 sequences con-
stituted either a 50 extension of a common exon (in case
of exon 1e) or mutually exclusive exons inside an existing
intron (in case of exons 1f through 1k) and belong to the
most common classes of alternative ﬁrst exons among
both humans and mice (51,57). We have by RT-PCR on
mouse tumor tissue identiﬁed potential intron 2-initiating
exons in addition to those reported here by 50 RACE, as
well as one in the region harboring the known exons 1a
through 1d (data not shown). We do not at present know
if these are expressed in normal tissue as well. Generally,
alternative promoter usage and subsequent use of alterna-
tive exons 1 is related to tissue- and temporal-speciﬁc
expressions (58–63). The molecular regulation of Jdp2
transcription is largely unknown except for the observa-
tion that several uncharacterized transcripts of various
sizes have been described in diﬀerent tissues (2,18). It is
thus tempting to connect the identiﬁed complex transcrip-
tion pattern of Jdp2 with the regulated expression of full-
length and truncated transcripts. Although we have not
addressed Jdp2 regulation speciﬁcally, the presented
expression analyses indicate tissue-speciﬁc expression of
both canonical and alternative Jdp2 mRNAs. For
instance, while skeletal muscle expresses relatively high
levels of both canonical and alternative transcripts
1e-3-4 and 1f-3-4 Jdp2, in brain tissue levels of 1f-3-4,
were relatively low while canonical and 1e-3-4 Jdp2
levels were high. Along this line, the absolute copy
number of isoform transcripts was judged to be in the
similar range as the canonical mRNA for some tissues,
such as Jdp2 1f-3-4 in skeletal muscle, which may indicate
a speciﬁc role in this tissue. Interestingly, Jdp2 has been
implicated in the diﬀerentiation of C2 myoblast cells (10).
Several factors inﬂuence the discrepancies observed
between mRNA and protein signal in some tissues such
as testis. First, we focused on the two most abundantly
expressed alternative transcripts as found in one tumor
and two normal tissue samples (bone marrow and brain)
by 50 RACE, and acknowledge that our expression
analyses were far from exhaustive. Hence, some of the
observed protein species are likely to derive from
sequences other than exons 1e and 1f. Our 50 RACE ana-
lysis intriguingly showed most alternative exons 1e and 1f
transcripts in bone marrow and brain to be initiated after
the start codons that were disclosed in tumor tissue.
Although an in-frame methionine codon exists in exon 4
allowing for production of a 54-amino-acid peptide by
these transcripts, any biological function of such peptide
is not obvious since it would lack part of the leucine zipper
domain of Jdp2. It should be mentioned, however,
that ATF3, which is the bZIP transcription factor most
related to Jdp2 (64), encodes a naturally occurring splice
variant ATF3DZip lacking the leucine zipper domain (65).
Despite lacking the ability to bind DNA, this isoform
antagonized ATF3 repression in a way that was specu-
lated to involve sequestering of inhibitory co-factors
(65). Second, diﬀerent involvement of post-transcriptional
regulation in various tissues is expected. Finally, the
sequence around the start AUG codon diﬀers among the
investigated transcripts. According to the most coherent
model for eukaryotic translation initiation ribosome pre-
initiation components are recruited near the 50 cap of the
mRNA and scan the 50UTR for the ﬁrst AUG codon to
start translation (reviewed in (66)). According to phyloge-
netic and genetic evidence (67–71) the ‘optimal’ nucleotide
context in terms of translation initiation eﬃciency is
GCC(A/G)CCAUGG (bold nucleotides are envisaged to
be the most important). From this the AUG context
in exon 1f (UGGAGAAUGG) would be predicted to be
considerably stronger than in the two encoded by exon 1e
4668 Nucleic Acids Research, 2009, Vol. 37,No. 14(GCUGAGAUGU for Jdp2-132, and CUGUCCAUGU
for Jdp2-119). It will be important to thoroughly charac-
terize the expression pattern of Jdp2 alternative exons
1 under various stress stimuli known to involve Jdp2
function.
Since little is known about the subcellular localization
of Jdp2 (15), we compared the localization pattern of full-
length and isoform Jdp2 by immunoﬂuorescence. We also
considered the possibility that the alternative N-termini
of the isoforms, and in particular the long alternative
N-terminus of Jdp2-132, could harbor signals involved
in subcellular localization. However, both Jdp2 and
Jdp2-132, Jdp2-119 and Jdp2-107 isoforms accumulated
exclusively to the nucleus on over-expression in murine
ﬁbroblasts. Hence, our results indicate that the N-termi-
nus of neither Jdp2 (residues 1-68) nor of the isoforms
contain important determinants involved in nuclear trans-
port. These, then, are likely to locate within the basic
DNA-binding region as for other AP-1 factors.
Retroviral activation of Jdp2 in T-cell lymphomas
of mice is currently the strongest evidence for a gain-of-
function potential of Jdp2 in cancer development in the
hematopoietic system. The observation that truncated
transcripts in some tumors were almost exclusively
up-regulated indicate a tumorigenic potential of Jdp2 iso-
forms lacking the N-terminus, which is involved in making
associations to histones and contributes a histone acetyla-
tion inhibitory (INHAT) capacity to Jdp2 (7). Other
tumor samples (mainly cluster B tumors) apparently
resulted in elevation of only canonical Jdp2. These obser-
vations are in line with the ﬁnding of increased anchorage-
independent growth potential of NRAS G12D both when
expressed together Jdp2 and Jdp2 isoforms lacking the
INHAT. It should be noted that in contrast to our ﬁnd-
ings, Heinrich et al. (21) reported full-length Jdp2
to repress oncogenic RasV12 transformation (21). We
speculate that a possible explanation could be related to
highly diﬀerent ectopic levels of Jdp2; by applying a LTR/
IRES-mediated expression strategy after retroviral trans-
duction, we dramatically lowered ectopic Jdp2 protein
levels as compared to SV40 promoter-driven expression
after plasmid transfection, and hence may have been
below a certain threshold for cellular toxicity responses,
or minimized squelching of Jdp2-dimerization partners by
ectopic Jdp2 not bound to DNA (72). In our clonogenic
assays, which were based upon plasmid transfection of
SV40 promoter-driven Jdp2 expression constructs fol-
lowed by selection for high transgene expression, we
observed lack of cell survival in the case of full-length as
well as isoform Jdp2 proteins. This result independently
demonstrates an eﬀect of Jdp2 isoforms lacking the
N-terminal INHAT domain.
The ﬁnding of a similar potential of full-length and
truncated Jdp2 in colony formation in the presence of
Nras G12D raises the possibility that the tumorigenic
role of retroviral activation of Jdp2 is independent of
the N-terminal repressive domain. Since some tumors
samples had low canonic RNA levels but high intron
2-derived transcripts (e.g. tumors 1161 and 1363), such a
scenario would predict that selection for MLV integra-
tions within Jdp2 be attributed solely to the ability to
activate the intron 2 promoters. An alternative possibility
is that full-length and truncated Jdp2 have separate roles
during T-cell lymhomagenesis. In favor of this model are
several indirect connections between transformation and
the Jdp2N-terminus. For instance, Blazek et al. (16) found
the N-terminus of Jdp2 indispensable for transformation
of chick embryo ﬁbroblasts and proposed the Jdp2-Fos
heterodimer as a likely candidate for this activity (16).
Also, the N-terminus, together with the DNA-binding
domain of Jdp2, was important in Jdp2-stimulated pro-
gesterone-dependent transcriptional activation by PR (8),
linking this part of Jdp2 to the homeostasis of female
reproductive tissue. Recently, Jdp2 was found to repress
transcription through consensus ATF/CRE sites of the
immediate early gene ATF3 (73), which in some models
appears to act as a tumor suppressor of Ras-mediated
tumorigenesis (74,75). Although the involvement of
Jdp2N-terminus was not speciﬁcally addressed, based on
well-established work on Jdp2 transcription repression
through ATF/CRE (1,2,7,16), ATF3 repression is likely
to require the INHAT domain of Jdp2 also. It thus
remains to be clariﬁed whether Jdp2 isoforms lacking an
inhibitory N-terminal domain but have retained the basic
and zipper domain encoded by exons 3 and 4 contribute
a dominant negative or a loss of function eﬀect to cellular
Jdp2-including protein complexes. In that regard, it would
be important to investigate how a deregulated balance
of Jdp2 isoforms, as found here in T-cell lymphomas,
impacts on AP-1 complex constituents and Jdp2 target
genes.
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